EP1086692A3 - Agonistes et antagonistes de l'estrogène pour des indications multiples - Google Patents

Agonistes et antagonistes de l'estrogène pour des indications multiples Download PDF

Info

Publication number
EP1086692A3
EP1086692A3 EP00305611A EP00305611A EP1086692A3 EP 1086692 A3 EP1086692 A3 EP 1086692A3 EP 00305611 A EP00305611 A EP 00305611A EP 00305611 A EP00305611 A EP 00305611A EP 1086692 A3 EP1086692 A3 EP 1086692A3
Authority
EP
European Patent Office
Prior art keywords
antagonists
estrogen agonists
multiple indications
warfarin
propranolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00305611A
Other languages
German (de)
English (en)
Other versions
EP1086692A2 (fr
Inventor
Li Julia Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of EP1086692A2 publication Critical patent/EP1086692A2/fr
Publication of EP1086692A3 publication Critical patent/EP1086692A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00305611A 1999-07-28 2000-07-03 Agonistes et antagonistes de l'estrogène pour des indications multiples Withdrawn EP1086692A3 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14607599P 1999-07-28 1999-07-28
US14607299P 1999-07-28 1999-07-28
US146075P 1999-07-28
US146072P 1999-07-28

Publications (2)

Publication Number Publication Date
EP1086692A2 EP1086692A2 (fr) 2001-03-28
EP1086692A3 true EP1086692A3 (fr) 2003-07-09

Family

ID=26843545

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00305611A Withdrawn EP1086692A3 (fr) 1999-07-28 2000-07-03 Agonistes et antagonistes de l'estrogène pour des indications multiples

Country Status (9)

Country Link
EP (1) EP1086692A3 (fr)
JP (1) JP2001048805A (fr)
KR (1) KR20010049909A (fr)
AU (1) AU4882700A (fr)
CA (1) CA2314572A1 (fr)
HU (1) HUP0002979A2 (fr)
IL (1) IL137428A0 (fr)
NZ (1) NZ506014A (fr)
PE (1) PE20010347A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436977B1 (en) * 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
GB2475907A (en) * 2009-12-04 2011-06-08 Tcp Innovations Ltd Composition comprising a mixture of clopidogrel and droloxifene
WO2018071437A1 (fr) * 2016-10-11 2018-04-19 Sermonix Pharmaceuticals, Llc Traitement au lasofoxifène de l'atrophie vulvovaginale (wa) et de l'ostéoporose chez des survivantes du cancer du sein ou d'autres malignités
JP6892151B2 (ja) 2016-10-11 2021-06-23 デューク ユニバーシティ Ｅｒ＋乳がんのラソフォキシフェン処置
EP3773524A4 (fr) 2018-04-10 2021-12-22 Duke University Traitement du cancer du sein avec du lasofoxifène
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"nablaRaloxifene to prevent postmenopausal osteoporosis", DRUG AND THERAPEUTICS BULLETIN 1999 UNITED KINGDOM, vol. 37, no. 5, 1999, pages 33 - 36, XP008016682, ISSN: 0012-6543 *
DELMAS PIERRE D ET AL: "Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.", NEW ENGLAND JOURNAL OF MEDICINE, vol. 337, no. 23, 4 December 1997 (1997-12-04), pages 1641 - 1647, XP008016674, ISSN: 0028-4793 *
GOLDSTEIN S R: "Selective estrogen receptor modulators: A new category of compounds to extend postmenopausal women's health", INTERNATIONAL JOURNAL OF FERTILITY AND WOMEN'S MEDICINE 1999 UNITED STATES, vol. 44, no. 5, September 1999 (1999-09-01), pages 221 - 226, XP008016605, ISSN: 1069-3130 *
GRASSER W A ET AL: "COMMON MECHANISM FOR THE ESTROGEN AGONIST AND ANTAGONIST ACTIVITIES OF DROLOXIFENE", JOURNAL OF CELLULAR BIOCHEMISTRY, WILEY-LISS INC, US, vol. 65, no. 2, 1997, pages 159 - 171, XP000971988, ISSN: 0730-2312 *
IBRAHIM N K ET AL: "NEW ANTIESTROGENS IN BREAST CANCER: A REVIEW", BREAST JOURNAL, BLACKWELL SCIENCE, CAMBRIDGE,, US, vol. 4, no. 4, 1998, pages 213 - 229, XP000913579, ISSN: 1075-122X *
LIEN E A ET AL: "Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy.", CANCER TREATMENT REVIEWS, vol. 26, no. 3, June 2000 (2000-06-01), pages 205 - 227, XP008016604, ISSN: 0305-7372 *
SCOTT J A ET AL: "Raloxifene: a selective estrogen receptor modulator.", AMERICAN FAMILY PHYSICIAN. UNITED STATES 15 SEP 1999, vol. 60, no. 4, 15 September 1999 (1999-09-15), pages 1131 - 1139, XP008016687, ISSN: 0002-838X *
SKERJANEC ANDREJ ET AL: "Pharmacokinetics and pharmacodynamic interaction study between raloxifene and warfarin.", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 14, no. 11 SUPPL., November 1997 (1997-11-01), Annual Meeting of the American Association of Pharmaceutical Scientists;Boston, Massachusetts, USA; November 2-6, 1997, pages S561 - S562, XP008016675, ISSN: 0724-8741 *
UMLAND ELENA M ET AL: "The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers.", ANNALS OF PHARMACOTHERAPY, vol. 33, no. 12, December 1999 (1999-12-01), pages 1315 - 1328, XP008016689, ISSN: 1060-0280 *

Also Published As

Publication number Publication date
CA2314572A1 (fr) 2001-01-28
HUP0002979A2 (hu) 2002-04-29
PE20010347A1 (es) 2001-03-23
AU4882700A (en) 2001-02-01
HU0002979D0 (en) 2000-10-28
NZ506014A (en) 2001-11-30
JP2001048805A (ja) 2001-02-20
EP1086692A2 (fr) 2001-03-28
IL137428A0 (en) 2001-07-24
KR20010049909A (ko) 2001-06-15

Similar Documents

Publication Publication Date Title
WO2001026693A3 (fr) Production de conjugues d'agents therapeutiques de polyglutamate
WO2002046477A3 (fr) Retrovirus endogenes regules positivement dans le cancer de la prostate
EP1992695A3 (fr) Antigène transmembranaire de la lectine de type C exprimé dans le cancer humain de la prostate et ses utilisations
WO2003077972A8 (fr) Systeme de distribution de medicament implantable
WO2001078702A3 (fr) Procedes et compositions de modulation de l'activite des recepteurs adrenergiques alpha
EP1363629A4 (fr) Ligands du recepteur kappa opioide
AU2987800A (en) Microwave antennas for medical hyperthermia, thermotherapy and diagnosis
AU1453602A (en) Systems, devices and methods for suturing patient tissue
AU6934300A (en) Tissue electroperforation for drug delivery and diagnostic sampling
AU2002252152A1 (en) Tissue electroperforation for enhanced drug delivery and sampling
AU2002322599A1 (en) Medical device with adjustable epidermal tissue ingrowth cuff
HK1053118A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof.
DE50004085D1 (de) Medizinisches, insbesondere chirurgisches instrument
WO2001078703A3 (fr) Methodes et compositions destinees a moduler l'activite des recepteurs adrenergiques alpha
PL340948A1 (en) Syringe, in particular that for taking blood samples from patients
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
EP1086692A3 (fr) Agonistes et antagonistes de l'estrogène pour des indications multiples
WO2001062784A3 (fr) Proteines
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
AU2001288921A1 (en) Human breast cancer biomarkers
ZA200110244B (en) Novel xanthone compounds, their preparation and use as medicament.
HK1033876A1 (en) Use of nmda antagonists for treatment of irritablebowel syndrome.
AU2002346049A1 (en) Coactivators in the diagnosis and treatment of breast cancer
AU2002366973A1 (en) Disposable garment for medical examination
EP1161254A4 (fr) Traitement des maladies auto-immunes avec un extrait de ginseng americain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000712

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61P 9/00 B

Ipc: 7A 61P 19/10 B

Ipc: 7A 61K 31/37 B

Ipc: 7A 61K 31/40 B

Ipc: 7A 61K 31/138 A

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040110